ACADVL
(Acyl-CoA Dehydrogenase, Very Long Chain (ACADVL))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
Produktmerkmale
This is a synthetic peptide designed for use in combination with anti-ACADVL antibody (Catalog #: ARP54486_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Konzentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
ACADVL
(Acyl-CoA Dehydrogenase, Very Long Chain (ACADVL))
Synonyme
ACAD6 Peptide, LCACD Peptide, VLCAD Peptide, vlcad Peptide, fb52d04 Peptide, wu:fb52d04 Peptide, wu:fc75e01 Peptide, zgc:64067 Peptide, acyl-CoA dehydrogenase very long chain Peptide, acyl-Coenzyme A dehydrogenase, very long chain Peptide, acyl-CoA dehydrogenase, very long chain Peptide, ACADVL Peptide, Acadvl Peptide, acadvl Peptide
Hintergrund
ACADVL is targeted to the inner mitochondrial membrane where it catalyzes the first step of the mitochondrial fatty acid beta-oxidation pathway. This acyl-Coenzyme A dehydrogenase is specific to long-chain and very-long-chain fatty acids. A deficiency in ACADVL protein reduces myocardial fatty acid beta-oxidation and is associated with cardiomyopathy.The protein encoded by this gene is targeted to the inner mitochondrial membrane where it catalyzes the first step of the mitochondrial fatty acid beta-oxidation pathway. This acyl-Coenzyme A dehydrogenase is specific to long-chain and very-long-chain fatty acids. A deficiency in this gene product reduces myocardial fatty acid beta-oxidation and is associated with cardiomyopathy. Alternative splicing results in multiple transcript variants encoding different isoforms.